U.S. Markets closed

Marker Therapeutics, Inc. (MRKR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7000+0.0100 (+0.59%)
At close: 4:00PM EST

1.7000 0.00 (0.00%)
After hours: 4:00PM EST

Sign in to post a message.
  • H
    Huck
    "The Fly" notes that Marker leadership met with Oppenheimer last Thursday and then Oppenheimer came out with a $8 target. I guess that's what Marker hired this sell-side entity to do.
  • r
    red arrow
    I looked at the website it appears we have multiple clinical studies going on. We have studies going on in lymphoma, multiple myeloma cancer, pancreatic cancer, and sarcoma. These studies are fully enrolled, in Phase 1, and could be advanced to Phase II. In Phase II we have studies going in Triple Breast Cancer and Ovarian Cancer.

    I'm not going to make any predictions on anything, but MRKR has the potential to breakout big one of these days. Patience and fortitude my friends!
  • G
    Gregg829
    It’s alive!
  • R
    R694
    Nice little jump this morning. Someone wanted to get in bad enough in the pre -hours to pay a premium for their 450 shares!
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is up 6.51% to 1.80
  • p
    peter
    The way forward for MRKR is to partner with a company that makes checkpoint molecules or be acquired by one. Multi-TAA needs to be supercharged with checkpoint blockade.
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is up 7.10% to 1.74
  • M
    MS
    @redplate MRKR extended the TPIV200 trial another year. What are we to interpret from that change? I'm imagining you are uniquely positioned, between your experience and expertise, to shed light on what might be going on with the extension. Thanks in advance for your help.
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is up 7.20% to 1.64
  • j
    jock nebraska
    Blast off for year end rally
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is up 6.99% to 1.53
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is up 7.59% to 1.56
  • j
    jonathan
    I’ve accumulated a great deal of mrkr over the years, think we are going to be rewarded for our patience over next year, good things are going to happen chaps and chapettes.
    Bullish
  • H
    Huck
    Didn't watch the Oppenheimer. Company Investors link not letting me see it after the fact. Anything?
  • S
    Sheridan
    Pancreatic cancer update is promising but who knows when aml trial will ever start. Our only hope. Is some partnership funding with big pharma on pancreatic cancer. COVID screwed mrkr and executives don’t deliver timeline results while we run thru cash. Very frustrating . Still think science is there but can’t figure out what mr. Kim is getting paid for unless he delivers and acceptable deal with big pharma. So far he hasn’t delivered
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is up 8.97% to 1.70
  • S
    Simon
    Catalysts....

    I see none of the radar - will avg done as this position is a sea of red. It just seems MRKR is stuck in the mud.

    BCLI - ALS phase III culminating in November, while Sarepta also should have an update to their gene therapy
    DMD treatment later this Fall. Something to look forward to.
  • Y
    Yahoo Finance Insights
    Marker Therapeutics is down 8.82% to 1.55
  • A
    Alexi
    Moved my remaining share to sls - there at least I know they have some catalysts due
  • S
    Simon
    Might as well use my MRKR stock certs to heat my house..